Radiative properties of stellar plasmas and open challenges

The lifetime of solar-like stars, the envelope structure of more massive stars, and stellar acoustic frequencies largely depend on the radiative properties of the stellar plasma. Up to now, these complex quantities have been estimated only theoretically. The development of the powerful tools of helio- and astero- seismology has made it possible to gain insights on the interiors of stars. Consequently, increased emphasis is now placed on knowledge of the monochromatic opacity coefficients. Here we review how these radiative properties play a role, and where they are most important. We then concentrate specifically on the envelopes of $\beta$ Cephei variable stars. We discuss the dispersion of eight different theoretical estimates of the monochromatic opacity spectrum and the challenges we need to face to check these calculations experimentally.Comment: 6 pages, 5 figures, in press (conference HEDLA 2010

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT80) biomarker—which quantifies the neutralization potency of antibodies in an individual’s serum against an HIV-1 isolate—can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT80 of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT80 <200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT80 biomarker as a surrogate endpoint for evaluatinon of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines

Current directions in co-crystal growth

In this feature article we will focus on the issues relating to the crystal growth of co-crystals, with a particular emphasis on drug development. The initial focus of this perspective is on the relevant literature examples that may be able to inform our understanding with regards co-crystal crystallisation and the allied supramolecular concepts. The second part of this perspective contains selected examples from our own work, which add to the literature perspective. Topics include; nucleation templates, in situ synchrotron XRD studies, solid-state synthesis through mixing and screening strategies